News & Updates

In the treatment of patients with advanced or recurrent endometrial carcinoma, adding the PD-L1 inhibitor atezolizumab to chemotherapy helps lower the risk of progression or death, according to the phase III AtTEnd trial.

Consumption of sugar-sweetened beverages appears to raise the risk of colorectal cancer (CRC), independent of CRC mortality, results of a meta-analysis have shown.

In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).

Among individuals with inflammatory bowel disease (IBD), histologic inflammation appears to contribute to an increased risk of serious infections such as sepsis, according to a study, suggesting that achieving remission may reduce infections in IBD.

Patients with breast cancer may gain greater therapeutic advantages from biomarker-driven than standard-of-care therapies, suggests a study.